🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Joy C. Yang

University of California, Davis

ORCID: 0000-0001-9162-481X
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer”.

Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-20-0015
N/A
0DataRank · unranked
82 citations

Shu Ning, Wei Lou, Joy C. Yang, Cameron M. Armstrong, Alan P. Lombard +5 more

Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling

Cancers(2021)10.3390/cancers13071672
N/A
0DataRank · unranked
14 citations

Zenghong Huang, Junjian Wang, Zhao Ma, Joy C. Yang, Eva Corey +4 more

The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer

Biomedicines(2022)10.3390/biomedicines10081778
N/A
0DataRank · unranked
40 citations

Logan J. Wasielewski, Joy C. Yang, Demin Cai, Christopher P. Evans, William J. Murphy +2 more

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-006581
N/A
0DataRank · unranked
68 citations

Joy C. Yang, Bo Chen, Christopher Nip, Jonathan E Van Dyke, Xiong Zhang +5 more

Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models

Pharmacological Research(2023)10.1016/j.phrs.2023.106692
N/A
0DataRank · unranked
22 citations

Joy C. Yang, Shu Ning, Bo Chen, Christopher Nip, Qiang Wei +7 more

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer

Oncogene(2023)10.1038/s41388-022-02566-6
N/A
0DataRank · unranked
21 citations

Pengfei Xu, Shu Ning, Logan J. Wasielewski, Hans Adomat, Sung Hee Hwang +9 more

895 Immunosuppressive signaling is activated in enzalutamide resistant prostate cancer

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0895
N/A
0DataRank · unranked
0 citations

Joy C. Yang, Bo Chen, Christopher Nip, Leyi Wang, Jonathan E. Van Dyke +4 more

Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer

Nature Communications(2024)10.1038/s41467-024-50459-x
N/A
0DataRank · unranked
10 citations

Joy C. Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang +16 more

Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer

Oncogene(2024)10.1038/s41388-024-03081-6
N/A
0DataRank · unranked
5 citations

Pengfei Xu, Joy C. Yang, Christopher Nip, Leyi Wang, Yuqiu Shen +9 more

Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer

Research Square(2024)10.21203/rs.3.rs-4095949/v1
N/A
0DataRank · unranked
0 citations

Bo Chen, Pengfei Xu, Joy C. Yang, Christopher Nip, Leyi Wang +9 more

Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer

Cancers(2025)10.3390/cancers17193187
N/A
0DataRank · unranked
2 citations

Huan Qu, Joy C. Yang, Wei Fan, Junwei Zhao, Menghuan Tang +9 more